Compare Boston Scientific Corporation (BSX) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs VanEck Junior Gold Miners — how do they compare? Boston Scientific Corporation trades at $43.37 (market cap $66.37B), while VanEck Junior Gold Miners trades at $97.56. The key difference: VanEck Junior Gold Miners is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | GDXJ | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $108.14 | $156.19 |
52-Week Low | $42.63 | $64.22 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
GDXJ (VanEck Junior Gold Miners ETF) trades at $95.40, down 3.55% with a bearish technical signal from moving averages. The fund has underperformed peers in 2026 with double-digit declines while other mining ETFs gained. Technical indicators show neutral oscillators but bearish momentum with key support at $92 and resistance at $97. Recent news highlights concerns about the fund's small-cap exposure and portfolio overlap issues.
The outlook remains challenging given GDXJ's 2026 underperformance and technical bearishness. Investment opportunity exists for contrarian bets on gold miner recovery, but risks include Federal Reserve policy uncertainty, weak small-cap gold miner fundamentals, and continued underperformance versus senior mining peers. The fund's high overlap with larger miners reduces diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
